[1]林 敏,郑 华,陈丽萌.1,5-脱水葡萄糖醇检测对短期血糖水平预测及临床新应用研究[J].现代检验医学杂志,2018,33(04):1-3，7.[doi:10.3969/j.issn.1671-7414.2018.04.001]
　LIN Min,ZHENG Hua,CHEN Li-meng.1,5-Anhydroglucitol as Short-term Glycemic Markers and Usage in Other Clinical Fields[J].Journal of Modern Laboratory Medicine,2018,33(04):1-3，7.[doi:10.3969/j.issn.1671-7414.2018.04.001]
点击复制

1,5-脱水葡萄糖醇检测对短期血糖水平预测及临床新应用研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年04期
页码:
1-3，7
栏目:
述评
出版日期:
2018-08-30

文章信息/Info

Title:
1,5-Anhydroglucitol as Short-term Glycemic Markers and Usage in Other Clinical Fields
文章编号:
1671-7414(2018)04-001-04
作者:
林 敏; 郑 华; 陈丽萌
中国医学科学院北京协和医院肾内科,北京 100730
Author(s):
LIN Min; ZHENG Hua; CHEN Li-meng
Departmentof Nephrology, Peking Union Medical College Hospital,Chinese Medical Science Academy,Beijing 100730,China
关键词:
1; 5-脱水葡萄糖醇;  血糖波动;  微血管病变;  心脑血管事件
分类号:
R446.12
DOI:
10.3969/j.issn.1671-7414.2018.04.001
文献标志码:
A
摘要:
1,5-脱水葡萄糖醇(1,5-anhydroglucitol,1,5-AG)是人体内广泛存在且化学性质稳定的单糖,其浓度在血糖正常时稳定,当血糖超过肾糖阈时降低,可用于监测短期血糖水平变化。近年来研究表明1,5-AG不仅可以增加早期糖尿病诊断的敏感度和特异度、监测妊娠期血糖波动和新生儿相关并发症; 在评估糖尿病相关微血管病变,预测心脑血管不良事件等方面也具有独特优势,此外它还直接参与血糖调节和炎症反应,是有较好临床应用前景的生物标志物。
Abstract:
Abstract:1,5-anhydroglucitol(1,5-AG)is a chemicallyinert monosaccharide widely distributed in the human body,whose concentrationis stable under normal serum glucose level but declines when serum glucose level exceeds the renal glucose threshold.1,5-AG can reflect short-term glycemiccontrol,especially serum glucose fluctuation and postprandial hyperglycemia.1,5-AG also shows superior sensitivity and specificity in early diagnosis of diabetes and notable value in gestational diabetes mellitus,neonatal complications,diabetes-related microangiopathy monitor,and cardiovascular and cerebrovascular adverse event prediction.In addition,1,5-AG directly participates in glucose metabolism and inflammatory reactions.In conclusion,1,5-AG has been proved as a promising clinical and academic biomarker.

参考文献/References:

[1] Xu Y,Wang H,He J,et al.Prevalence and control of diabetes in Chinese adults[J].JAMA:Journal of the American Medical Association,2013,310(9):948-959.
[2] Yamanouchi T,Moromizato H,Shinohara T,et al.Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol[J].Metabolism:Clinical and Experimental,1992,41(8):862-867.
[3] Nakamura S,Tanabe K,Yoshinaga K,et al.Effects of 1,5-anhydroglucitol on postprandial blood glucose and insulin levels and hydrogen excretion in rats and healthy humans[J].The British Journal of Nutrition,2017,118(2):81-91.
[4] Tazawa S,Yamato T,Fujikura H,et al.SLC5A9/SG LT4,a new Na+-dependent glucose transporter,is an essential transporter for mannose,1,5-anhydro-D-glucitol,and fructose[J].Life Sciences,2005,76(9):1039-1050.
[5] Halama A,Kulinski M,Kader SA,et al.Measurement of 1,5-anhydroglucitol in blood and saliva:from non-targeted metabolomics to biochemical assay[J].Journal of Translational Medicine,2016,14(1):140.
[6] Mook-Kanamori DO,Selim MM,Takiddin AH,et al.1,5-Anhydroglucitol insaliva is a noninvasive marker of short-term glycemic control[J].The Journal of Clinical Endocrinology and Metabolism,2014,99(3):E479-E483.
[7] 潘利琴,张德亭,连国军,等.以WST-5为色源脱氢酶法测定血清1,5-AG含量[J].中国卫生检验杂志,2013,23(3):688-690. Pan LQ,Zhang DT,Lian GJ,et al.A new enzymaitic method for determination of 1,5 anhydro-D-glucitol in serum using WST-5 as a color source[J].Chinese Journal of Health Laboratory Technology,2013,23(3):688-690.
[8] Malkan UY,Gunes G,Corakci A.Rational diagnoses of diabetes:the comparison of 1,5-anhydroglucitol with other glycemic markers[J].Springer Plus,2015,4(1):587.
[9] 王洋一,胡宏章.在不同性别及年龄间糖化血红蛋白水平差异分析[J].现代检验医学杂志,2017,32(2):123-125,130. Wang YY,Hu HZ.Differential analysis of glycosylated hemoglobin indifferent sex and age[J].Journal of Modern Laboratory Medicine,2017,32(2):123-125,130.
[10] Wang Y,Bai Y,Yang R,et al.Serum 1,5-anhydroglucitol concentrations remain valid as a glycemic control marker in diabetes with earlier chronic kidney disease stages[J].Experimental and Clinical Endocrinology & Diabetes,2017 doi:10.1055/S-0043-122142[Epub aheaa of print].
[11] Wang Y,Yuan Y,Zhang Y,et al.Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes[J].Acta Diabetologica,2017,54(5):425-431.
[12] Su H,Ma X,Yin J,et al.Serum 1,5-anhydroglucitol levels slightly increase rather than decrease after a glucose load in subjects with different glucose tolerance status[J].Acta Diabetologica,2017,54(5):463-470.
[13] Wright LA,Hirsch IB,Gooley TA,et al.1,5-anhydroglucitol and neonatal complications in pregnancy complicated by diabetes[J].Endocrine Practice,2015,21(7):725-733.
[14] Dworacka M,Winiarska H,Borowska M,et al.Pro-atherogenic alterationsin T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients[J].Circ J,2007,71(6):962-967.
[15] Yu B,Zheng Y,Nettleton JA,et al.Serum metabolomic profiling and incident CKD among African Americans[J].Clinical Journal of the American Societyof Nephrology,2014,9(8):1410-1417.
[16] Rebholz CM,Grams ME,Chen Y,et al.Serum levels of 1,5-anhydroglucitol and risk of incident end-stage renal disease[J].American Journal of Epidemiology,2017,186(8):952-960.
[17] Liang M,McEvoy JW,Chen Y,et al.Association of a biomarker of glucosepeaks,1,5-anhydroglucitol,with subclinical cardiovascular disease[J].Diabetes Care,2016,39(10):1752-1759.
[18] Fujiwara T,Yoshida M,Akashi N,et al.Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention[J].Heart and Vessels,2016,31(6):855-862.
[19] Takahashi S,Shimada K,Miyauchi K,et al.Low and exacerbated levels of1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention[J].CardiovascularDiabetology,2016,15(1):145.
[20] Meng X,Tancharoen S,Kawahara KI,et al.1,5-Anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions[J].International Journal of Immunopathology and Pharmacology,2010,23(1):105-119.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81470937,81641024),国家重点研发计划“精准医学”重点专项(2016YFC0901500),宁夏回族自治区重点研发计划(对外科技合作专项)东西部合作项目(2018YBZD0557),中国医学科学院医学与健康科技创新工程经费资助(2016-12M-2-004),北京协和医学院教学改革基金(2016zlgc0103),中国医学科学院协和学者基金。 作者简介:林 敏(1994-),女,在读博士,临床医学专业学习中,Tel:010-65295058,E-mail:linpumc@126.com。 通讯作者:陈丽萌(1971-),女,博士,教授,主任医师,博士生导师,从事原发和继发肾脏病研究,Tel:010-69155058,E-mail:chenlimeng@pumch.cn。
更新日期/Last Update: 2018-08-16